Caris Life Sciences Human Leukocyte Antigen Genotype Reporting
Caris Life Sciences has launched Human Leukocyte Antigen (HLA) Genotype reporting. The product strengthens physicians' ability to provide more individualized treatment decisions for their patients, and the results may also provide additional insight for patient enrollment into clinical trials and patients' response to immunotherapy, the company said.
Effective immediately, HLA Genotype results will be reported as a genomic signature, along with tumor mutational burden, microsatellite instability, and loss of heterozygosity as standard reporting elements for patients profiled by Caris.